Abstract
Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine.
Original language | English (US) |
---|---|
Pages (from-to) | 1169-1173 |
Number of pages | 5 |
Journal | Vaccine |
Volume | 32 |
Issue number | 10 |
DOIs | |
State | Published - Feb 26 2014 |
Externally published | Yes |
Fingerprint
Keywords
- Dyskeratosis congenita
- Fanconi anemia
- Human papillomavirus
- Inherited bone marrow failure syndromes
- Vaccine
ASJC Scopus subject areas
- Immunology and Microbiology(all)
- Infectious Diseases
- Public Health, Environmental and Occupational Health
- veterinary(all)
- Molecular Medicine
Cite this
Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes. / Alter, Blanche P.; Giri, Neelam; Pan, Yuanji; Savage, Sharon A.; Pinto, Ligia A.
In: Vaccine, Vol. 32, No. 10, 26.02.2014, p. 1169-1173.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes
AU - Alter, Blanche P.
AU - Giri, Neelam
AU - Pan, Yuanji
AU - Savage, Sharon A.
AU - Pinto, Ligia A.
PY - 2014/2/26
Y1 - 2014/2/26
N2 - Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine.
AB - Patients with Fanconi anemia (FA) and other inherited bone marrow failure syndromes (IBMFS) have extremely high risks of squamous cell head and neck, and gynecologic carcinomas. In the general population, these sites are often associated with infection with human papillomaviruses (HPV), particularly HPV16 and HPV18. Our objectives were to measure the levels of HPV antibodies in unvaccinated patients, and to determine whether these patients developed and maintained similar levels of antibodies as those observed in healthy women, following vaccination with the currently licensed HPV L1 virus-like particles (VLP) vaccines. We measured anti-HPV IgG antibody levels in sera from patients using an HPV16 or HPV18 L1 VLP enzyme-linked immunoabsorbent assay. Most unvaccinated patients did not have detectable antibody levels, except for a few women above age 25. Both FA and other IBMFS patients developed antibody levels following vaccination that were similar to those previously described in healthy women, and those levels appeared to be sustained out to 5 years after immunization. Thus, antibody responses to the HPV L1 VLP vaccine in patients with FA and other IBMFS appeared to be similar to the responses reported in the general population, implying potential efficacy against future infections with the HPV types contained in the vaccine.
KW - Dyskeratosis congenita
KW - Fanconi anemia
KW - Human papillomavirus
KW - Inherited bone marrow failure syndromes
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=84893946909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893946909&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2013.11.048
DO - 10.1016/j.vaccine.2013.11.048
M3 - Article
C2 - 24295807
AN - SCOPUS:84893946909
VL - 32
SP - 1169
EP - 1173
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 10
ER -